Elevated DCP values (≥7.5 ng/mL) have been shown to be associated with a 5-fold increased risk of developing HCC, and on this basis, DCP has received Food and Drug Administration (FDA) approval for risk assessment. The gene discussed is ACE; the disease is hepatocellular carcinoma.